These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 34923762)
1. Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants. Liu J; Bodnar BH; Padhiar NH; Khan AI; Meng F; Saribas S; Wang P; Wang X; McCluskey E; Shah S; Zhao H; Luo JJ; Hu WH; Ho WZ Clin Transl Med; 2021 Dec; 11(12):e644. PubMed ID: 34923762 [No Abstract] [Full Text] [Related]
2. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines. Wang Y EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128 [No Abstract] [Full Text] [Related]
3. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Zeng C; Evans JP; Chakravarthy K; Qu P; Reisinger S; Song NJ; Rubinstein MP; Shields PG; Li Z; Liu SL Cancer Cell; 2022 Feb; 40(2):117-119. PubMed ID: 34986328 [No Abstract] [Full Text] [Related]
5. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD; Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254 [TBL] [Abstract][Full Text] [Related]
6. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961 [TBL] [Abstract][Full Text] [Related]
7. Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases. Bakasis AD; Bitzogli K; Mouziouras D; Pouliakis A; Roumpoutsou M; Goules AV; Androutsakos T Viruses; 2022 Jan; 14(2):. PubMed ID: 35215801 [TBL] [Abstract][Full Text] [Related]
8. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Saxton M; Piantadosi A; Waggoner JJ; Douek DC; Rouphael N; Wrammert J; Suthar MS Cell Rep Med; 2022 Feb; 3(2):100529. PubMed ID: 35233550 [TBL] [Abstract][Full Text] [Related]
9. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S Front Immunol; 2021; 12():793191. PubMed ID: 34975897 [TBL] [Abstract][Full Text] [Related]
10. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448 [TBL] [Abstract][Full Text] [Related]
11. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197 [TBL] [Abstract][Full Text] [Related]
12. Establishment of human post-vaccination SARS-CoV-2 standard reference sera. Xiang J; Katz L; Winokur PL; Chaudhary A; Digmann B; Bradford R; Rashid S; Ghosh S; Robertson A; Menetski J; Xu M; Gao P; Chen CZ; Lee T; Poelaert B; Eastman RT; Hall MD; Stapleton JT J Immunol Methods; 2024 Jul; 530():113698. PubMed ID: 38823574 [TBL] [Abstract][Full Text] [Related]
13. Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273. Gillot C; Tré-Hardy M; Cupaiolo R; Blairon L; Wilmet A; Beukinga I; Dogné JM; Douxfils J; Favresse J Virology; 2024 Jul; 595():110082. PubMed ID: 38636363 [TBL] [Abstract][Full Text] [Related]
14. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Stampfer SD; Goldwater MS; Jew S; Bujarski S; Regidor B; Daniely D; Chen H; Xu N; Li M; Green T; Fung E; Aquino E; Swift R; Eshaghian S; Preugschat K; Feinstein AJ; Spektor TM; Berenson JR Leukemia; 2021 Dec; 35(12):3534-3541. PubMed ID: 34326466 [TBL] [Abstract][Full Text] [Related]
15. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals. Uprichard SL; O'Brien A; Evdokimova M; Rowe CL; Joyce C; Hackbart M; Cruz-Pulido YE; Cohen CA; Rock ML; Dye JM; Kuehnert P; Ricks KM; Casper M; Linhart L; Anderson K; Kirk L; Maggiore JA; Herbert AS; Clark NM; Reid GE; Baker SC Viruses; 2022 Feb; 14(2):. PubMed ID: 35215962 [TBL] [Abstract][Full Text] [Related]
16. Immune Response to COVID-19 Vaccination in Elite Athletes. Halmans L; Venhorst A; Klemis V; Schmidt T; Greiß F; Sester U; Gärtner BC; Sester M; Meyer T Exerc Immunol Rev; 2024; 30():63-70. PubMed ID: 39094182 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033 [TBL] [Abstract][Full Text] [Related]
18. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2. Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M Front Immunol; 2022; 13():811020. PubMed ID: 35126395 [TBL] [Abstract][Full Text] [Related]
19. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex. Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788 [TBL] [Abstract][Full Text] [Related]
20. Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination. Rosati M; Terpos E; Agarwal M; Karalis V; Bear J; Burns R; Hu X; Papademetriou D; Ntanasis-Stathopoulos I; Trougakos IP; Dimopoulos MA; Pavlakis GN; Felber BK Am J Hematol; 2022 Jan; 97(1):E3-E7. PubMed ID: 34674297 [No Abstract] [Full Text] [Related] [Next] [New Search]